Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.

Bo WangBingkun ZhouJunyu ChenXi SunWenjuan YangTenghao YangHao YuPeng ChenKe ChenXiaodong HuangXinxiang FanWang HeJian HuangTianxin Lin

Published in: Journal for immunotherapy of cancer (2024)

Our study indicated that IFN-λ3 enables macrophage-mediated phagocytosis and antitumor immune responses and suggests a rationale for using Type III IFN as a predictive biomarker and potential immunotherapeutic candidate for bladder cancer.

Keyphrases

type iii
immune response
dendritic cells
adipose tissue
toll like receptor
human health
risk assessment
climate change
muscle invasive bladder cancer